Literature DB >> 23284098

The Year in Cardiology 2012: focus on cardiovascular disease prevention.

Marietta Charakida1, Stefano Masi, John Eric Deanfield.   

Abstract

Current data suggest that advances in cardiovascular (CV) treatment have resulted in significant reduction in CV mortality but also in prolongation of life with disability. Focus on CV prevention is likely to reverse this unfavourable trend. In this review we provide information on the new European guidelines on CV prevention and discuss biomarkers and vascular imaging techniques which can assist in refining CV risk prediction. Finally, we provide new information on lifestyle and pharmacological advances which are likely to result in significant CV risk reduction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23284098     DOI: 10.1093/eurheartj/ehs429

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  2 in total

1.  HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative.

Authors:  Seth S Martin; Arif A Khokhar; Heidi T May; Krishnaji R Kulkarni; Michael J Blaha; Parag H Joshi; Peter P Toth; Joseph B Muhlestein; Jeffrey L Anderson; Stacey Knight; Yan Li; John A Spertus; Steven R Jones
Journal:  Eur Heart J       Date:  2014-06-30       Impact factor: 29.983

2.  Adipose Tissue Dysfunction and Altered Systemic Amino Acid Metabolism Are Associated with Non-Alcoholic Fatty Liver Disease.

Authors:  Sulin Cheng; Petri Wiklund; Reija Autio; Ronald Borra; Xiaowei Ojanen; Leiting Xu; Timo Törmäkangas; Markku Alen
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.